voruciclib
Clinical- Indications
- Triple negative breast cancer
Company intelligence / Profile preview
Presage has completed a first-of-its-kind Phase 0 clinical study utilizing its CIVO multiplexed microdosing platform. The company is conducting Phase 0 trials with multiple biotech partners to evaluate drug candidates directly in human tumors[1][6].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Presage Biosciences.